Houston made a big leap back into the top 50, ranking No. 40, after previously plummeting into No. 72 last year. Photo by Natalie Harms/InnovationMap

Lively Houston has regained its rightful place among the top 50 best cities in the world, according to a prestigious new report by Resonance Consultancy.

The Canada-based real estate and tourism marketing advisors ranked Houston the 40th best city worldwide for 2025 in its annual "World's Best Cities" list.

The report quantifies the relative qualities of livability, "lovability," and prosperity for the world's top 100 cities with metropolitan populations of 1 million or more. New to the 10th anniversary edition, Resonance partnered with global market researchers Ipsos to include perception-based data into the rankings, surveying over 22,000 people in 30 countries worldwide to determine "the most desirable places to visit, live or work."

Houston made a major rebound after plummeting to No. 66 in last year's report. In 2022, Houston ranked No. 42.

Resonance refers to its previous "World's Best Cities" reports and its 2024 "America's Best Cities" list – which ranked Houston in the top 10 – when explaining the Bayou City's successes. The report praised Houston's vast cultural diversity and placed a great focus on its economic prosperity, even going so far as to suggest Houston residents make more money "and can sock more away."

"...[W]here America’s fourth-largest city truly takes off is in its economic heft and wealth, ranking No. 9 globally for GDP per Capita and No. 14 for Fortune 500 companies in town," the report said. "All that rolls up into an overall Prosperity index ranking of No. 36, which is even more impressive given the No. 14-ranked Price-to Income Ratio [of the city]."

Elsewhere in Texas, Austin and Dallas also earned spots on the World's Best Cities list for 2025, but only one made a similar rebound from the previous year's rankings. Dallas moved up from No. 66 in last year's report to its current rank as No. 55. Meanwhile, Austin took its first tumble out of the 43rd spot (which it had occupied for two years straight) and now ranks No. 53.

London held onto its crown as the No. 1 best city in the world for 2025, followed by New York (No. 2), Paris (No. 3), Tokyo (No. 4), and Singapore (No. 5).

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.